OTC · RDGL
Healthcare · Medical - Devices
$0.04
Down-$0.00 (-0.47%)
Updated Nov 5, 2026, 5:16 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RDGL
1M range · 0 trading sessions · Daily adjusted prices
RDGL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RDGL.
Company
Market Activity
Research & News
RDGL research
Company profile and research snapshot.
VIVOS INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 29, 2026
This release removes the mention of Cleveland Clinic Weston.Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic disease patientsVERO BEACH, FL / ACCESS Newswire / October 29, 2026 / SOD Sciences, Inc.
Yahoo · Oct 21, 2026
LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on October 20, 2026
Yahoo · Oct 20, 2026
Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic‑disease patientsVERO BEACH, FL / ACCESS Newswire / October 20, 2026 / SOD Sciences, Inc. ("SOD Sciences" or "SOD") today announced the closing of its strategic partnership with Vivos Therapeutics, Inc.
Yahoo · Oct 19, 2026
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit OpportunitiesLITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos” or the “Company”) today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. (“SOD Sciences” or “SOD”) and a 50% undivided co-ownership interest in SOD's pseudohypoxia early‑warning
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDGL.
